CN113195452A - 多奈必利作为治疗神经退行性疾病中的神经保护剂 - Google Patents

多奈必利作为治疗神经退行性疾病中的神经保护剂 Download PDF

Info

Publication number
CN113195452A
CN113195452A CN201980063618.3A CN201980063618A CN113195452A CN 113195452 A CN113195452 A CN 113195452A CN 201980063618 A CN201980063618 A CN 201980063618A CN 113195452 A CN113195452 A CN 113195452A
Authority
CN
China
Prior art keywords
compound
mice
group
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980063618.3A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里克·达勒马涅
克里斯托夫·罗谢
西尔维·克莱森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Institute Of Health And Medicine
Centre National de la Recherche Scientifique CNRS
Universite de Caen Normandie
Universite de Montpellier
Original Assignee
French National Institute Of Health And Medicine
Centre National de la Recherche Scientifique CNRS
Universite de Caen Normandie
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French National Institute Of Health And Medicine, Centre National de la Recherche Scientifique CNRS, Universite de Caen Normandie, Universite de Montpellier filed Critical French National Institute Of Health And Medicine
Publication of CN113195452A publication Critical patent/CN113195452A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980063618.3A 2018-09-28 2019-09-27 多奈必利作为治疗神经退行性疾病中的神经保护剂 Pending CN113195452A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306280.1 2018-09-28
EP18306280.1A EP3628660A1 (en) 2018-09-28 2018-09-28 Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases
PCT/EP2019/076229 WO2020065028A1 (en) 2018-09-28 2019-09-27 Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CN113195452A true CN113195452A (zh) 2021-07-30

Family

ID=63798921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980063618.3A Pending CN113195452A (zh) 2018-09-28 2019-09-27 多奈必利作为治疗神经退行性疾病中的神经保护剂

Country Status (10)

Country Link
US (1) US20220031680A1 (https=)
EP (2) EP3628660A1 (https=)
JP (1) JP2022511366A (https=)
KR (1) KR20210098429A (https=)
CN (1) CN113195452A (https=)
AU (1) AU2019346024B2 (https=)
BR (1) BR112021005952A2 (https=)
CA (1) CA3115342A1 (https=)
SG (1) SG11202103070VA (https=)
WO (1) WO2020065028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3166060A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Composition pharmaceutique formulée pour être administrée par voie intranasale et utilisable pour le traitement d’une maladie neurodégénérative
FR3166146A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-[1-(cycloheptylméthyl)-4-pipéridinyl]propan-1-one –Composition pharmaceutique et utilisation associées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102355902A (zh) * 2009-01-24 2012-02-15 植物药物公共有限公司 神经营养因子介导的病症的处理
US20160122300A1 (en) * 2013-06-05 2016-05-05 Universite De Caen Acetylcholinesterase inhibitor compounds and 5ht4 serotonergic receptor agonists, with promnsia effect, methods for the preparation thereof and pharmaceutical compositions containing the same
US20160311797A1 (en) * 2013-12-16 2016-10-27 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
FR2904113A1 (fr) 2006-07-21 2008-01-25 Exonhit Therapeutics S A Sa Procedes et outils pour la therapie de pathologies neurodegeneratives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102355902A (zh) * 2009-01-24 2012-02-15 植物药物公共有限公司 神经营养因子介导的病症的处理
US20160122300A1 (en) * 2013-06-05 2016-05-05 Universite De Caen Acetylcholinesterase inhibitor compounds and 5ht4 serotonergic receptor agonists, with promnsia effect, methods for the preparation thereof and pharmaceutical compositions containing the same
US20160311797A1 (en) * 2013-12-16 2016-10-27 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JULIEN LALUT，等: "Modulating 5-HT4 and 5-HT6 receptors in Alzheimer\'s disease treatment", FUTURE MEDICINAL CHEMISTRY, vol. 9, no. 8, 15 May 2017 (2017-05-15), pages 781 - 795 *
KEVIN BARANGER，等: "Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer\'s disease", NEUROPHARMACOLOGY, vol. 126, 26 August 2017 (2017-08-26), pages 128 - 141 *
SAMIR YAHIAOUI，等: "Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer\'s disease", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 121, 26 May 2016 (2016-05-26), pages 283 - 293, XP029685745, DOI: 10.1016/j.ejmech.2016.05.048 *
于平，等: "5-羟色胺受体对记忆的调节作用", 首都师范大学学报(社会科学版), no. 4, 31 December 2009 (2009-12-31), pages 141 - 145 *

Also Published As

Publication number Publication date
WO2020065028A1 (en) 2020-04-02
AU2019346024B2 (en) 2024-07-18
JP2022511366A (ja) 2022-01-31
EP3628660A1 (en) 2020-04-01
AU2019346024A1 (en) 2021-04-29
SG11202103070VA (en) 2021-04-29
CA3115342A1 (en) 2020-04-02
BR112021005952A2 (pt) 2021-06-29
KR20210098429A (ko) 2021-08-10
US20220031680A1 (en) 2022-02-03
EP3856716A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
Urano et al. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β‐induced neurite atrophy
Weng et al. Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases
Faivre et al. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model
JP6574769B2 (ja) 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
Lee et al. 4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway
El-Mehi et al. Controlled ozone therapy modulates the neurodegenerative changes in the frontal cortex of the aged albino rat
Bai et al. Chlorzoxazone exhibits neuroprotection against Alzheimer’s disease by attenuating neuroinflammation and neurodegeneration in vitro and in vivo
CN113195452A (zh) 多奈必利作为治疗神经退行性疾病中的神经保护剂
Liu et al. Depression exacerbates AD pathology through lactate-dependent activation of microglial Kv1. 3 to promote Aβ-containing exosome spreading
JP5968878B2 (ja) イソアクテオシドまたはその製薬上許容される塩の使用
US20210338647A1 (en) Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases
RU2800802C2 (ru) Донекоприд как нейропротекторный агент при лечении нейродегенеративных заболеваний
CN118421606A (zh) Bace1多肽及其应用
US20170246245A1 (en) Novel pharmaceutical composition for treating alzheimer's disease
Zhang et al. Mice with the Rab10 T73V mutation exhibit anxiety-like behavior and alteration of neuronal functions in the striatum
CN115919822A (zh) 泛硫乙胺在治疗阿尔茨海默病中的应用
US20220143103A1 (en) Composition for preventing or treating neuroinflammatory disorders, comprising bee venom extract as active ingredient
Liu et al. Blockage of IL-17 ameliorates Aβ-induced neurotoxicity and cognitive decline
CN119868375B (zh) 艾地骨化醇联合利培酮在改善精神分裂症同时防治利培酮副作用骨质疏松症中的应用
WO2020082941A1 (zh) 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
Wang et al. Neuroprotective Effect of Hydroxysafflor Yellow A on an Alzheimer’s Disease (AD)-Like Mouse Model
Chelliah Altered proteostasis in a mouse model of huntington’s disease: Insights into pathogenic dysfunction and therapeutic modulation
Falkon Endo/Lysosomal Uptake and Degradation of Protein Aggregates in Tauopathy
Abdalla THE POTENT AND SELECTIVE HISTAMINE H3 RECEPTOR ANTAGONIST E169 ALLEVIATES COGNITIVE DEFICITS AND MITIGATES DISTURBED PI3K/AKT/GSK-3β SIGNALING PATHWAY IN MK801-INDUCED AMNESIA IN MICE
Yang et al. Benzene, 1, 2, 4-Trimethoxy-5-(2-Methyl-1-Propen-1-yl) Attenuates D-galactose/AlCl3-induced Cognitive Impairment by Inhibiting Inflammation, Apoptosis, and improving Expression of Memory-Related Proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210730